{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:11:50Z","timestamp":1790727110121,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748 CCITLA"],"award-info":[{"award-number":["P30 CA008748 CCITLA"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000982","name":"Conquer Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.esmoop.2025.104300","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T15:33:56Z","timestamp":1740152036000},"page":"104300","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["A phase I, first-in-human trial of KO-947, an ERK1\/2 inhibitor, in patients with advanced solid tumors"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6070-2413","authenticated-orcid":false,"given":"A.M.","family":"Schram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Boni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.A.","family":"Adjei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.J.","family":"Olszanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Vieito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.H.","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kurman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Ahsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Tomkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Garralda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2025.104300_bib1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.phrs.2019.03.006","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors","volume":"144","author":"Roskoski","year":"2019","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.esmoop.2025.104300_bib2","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/9250757","article-title":"How the BRAF V600E mutation defines a distinct subgroup of colorectal cancer: molecular and clinical implications","volume":"2018","author":"Bond","year":"2018","journal-title":"Gastroenterol Res Pract"},{"issue":"26","key":"10.1016\/j.esmoop.2025.104300_bib3","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.esmoop.2025.104300_bib4","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"9839","key":"10.1016\/j.esmoop.2025.104300_bib5","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.esmoop.2025.104300_bib6","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.esmoop.2025.104300_bib7","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRAS(G12C) inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.esmoop.2025.104300_bib8","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non-small-cell lung cancer harboring a KRAS(G12C) mutation","volume":"387","author":"Janne","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.esmoop.2025.104300_bib9","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nrd4281","article-title":"Targeting RAS-ERK signalling in cancer: promises and challenges","volume":"13","author":"Samatar","year":"2014","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.esmoop.2025.104300_bib10","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.21037\/tlcr.2019.10.22","article-title":"Targeting BRAF mutations in non-small cell lung cancer","volume":"8","author":"O\u2019Leary","year":"2019","journal-title":"Transl Lung Cancer Res"},{"issue":"2","key":"10.1016\/j.esmoop.2025.104300_bib11","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1158\/2159-8290.CD-17-1119","article-title":"First-in-class ERK1\/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: results of a phase I dose-escalation and expansion study","volume":"8","author":"Sullivan","year":"2018","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.esmoop.2025.104300_bib12","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.92352","article-title":"Development of MK-8353, an orally administered ERK1\/2 inhibitor, in patients with advanced solid tumors","volume":"3","author":"Moschos","year":"2018","journal-title":"JCI Insight"},{"issue":"12","key":"10.1016\/j.esmoop.2025.104300_bib13","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.1021\/acs.jmedchem.6b00389","article-title":"Discovery of (S)-1-(1-(4-chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an extracellular signal-regulated kinase 1\/2 (ERK1\/2) inhibitor in early clinical development","volume":"59","author":"Blake","year":"2016","journal-title":"J\u00a0Med Chem"},{"issue":"6","key":"10.1016\/j.esmoop.2025.104300_bib14","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1158\/1078-0432.CCR-19-2574","article-title":"A\u00a0first-in-human phase I study to evaluate the ERK1\/2 inhibitor GDC-0994 in patients with advanced solid tumors","volume":"26","author":"Varga","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"suppl 15","key":"10.1016\/j.esmoop.2025.104300_bib15","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1200\/JCO.2019.37.15_suppl.3001","article-title":"A\u00a0phase I dose escalation (DE) study of ERK inhibitor, LY3214996, in advanced (adv) cancer (CA) patients (pts)","volume":"37","author":"Pant","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2025.104300_bib16","article-title":"ASN007 is a selective ERK1\/2 inhibitor with preferential activity against RAS- and RAF-mutant tumors","volume":"2","author":"Portelinha","year":"2021","journal-title":"Cell Rep Med"},{"issue":"suppl 12","key":"10.1016\/j.esmoop.2025.104300_bib17","first-page":"TARG-19","article-title":"Phase 1 clinical safety and efficacy of ASN007, a novel oral ERK1\/2 inhibitor, in patients with RAS, RAF or MEK mutant advanced solid tumors","volume":"18","author":"Tolcher","year":"2019","journal-title":"Mol Cancer Ther"},{"issue":"suppl 13","key":"10.1016\/j.esmoop.2025.104300_bib18","doi-asserted-by":"crossref","first-page":"5168","DOI":"10.1158\/1538-7445.AM2017-5168","article-title":"Abstract 5168: KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK\u00a0pathway dysregulated tumors","volume":"77","author":"Burrows","year":"2017","journal-title":"Cancer Res"},{"issue":"suppl 13","key":"10.1016\/j.esmoop.2025.104300_bib19","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1158\/1538-7445.AM2018-3885","article-title":"Abstract 3885: 11q13 amplification selects for sensitivity to the ERK inhibitor KO-947 in squamous cell carcinomas","volume":"78","author":"Burrows","year":"2018","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2025.104300_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"issue":"12","key":"10.1016\/j.esmoop.2025.104300_bib21","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.oret.2021.06.001","article-title":"Clinical and morphologic characteristics of extracellular signal-regulated kinase inhibitor-associated retinopathy","volume":"5","author":"Francis","year":"2021","journal-title":"Ophthalmol Retina"},{"issue":"3","key":"10.1016\/j.esmoop.2025.104300_bib22","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.trecan.2015.10.001","article-title":"Targeting RAS-mutant cancers: is ERK the key?","volume":"1","author":"Ryan","year":"2015","journal-title":"Trends Cancer"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925001681?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925001681?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T10:44:30Z","timestamp":1762598670000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925001681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2059702925001681"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.104300","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase I, first-in-human trial of KO-947, an ERK1\/2 inhibitor, in patients with advanced solid tumors","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.104300","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Kura Oncology, Inc. and The Author(s). \u00a0Published by Elsevier Ltd. on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"104300"}}